| Literature DB >> 35471418 |
Roland Duculan, Deanna Jannat-Khah, Xin A Wang1, Carol A Mancuso.
Abstract
OBJECTIVE: In a cohort assembled during the height of mortality-associated coronavirus disease 2019 (COVID-19) in New York City, the objectives of this qualitative-quantitative mixed-methods study were to assess COVID-related stress at enrollment with subsequent stress and clinical and behavioral characteristics associated with successful coping during longitudinal follow-up.Entities:
Mesh:
Year: 2022 PMID: 35471418 PMCID: PMC9336210 DOI: 10.1097/RHU.0000000000001846
Source DB: PubMed Journal: J Clin Rheumatol ISSN: 1076-1608 Impact factor: 3.902
Demographic and Clinical Characteristics at Enrollment and Follow-up
| Variables | |
|---|---|
| Enrollment | |
| Age, mean (range), y | 50 (22–87) |
| Women | 83% |
| Race | |
| Asian | 8% |
| Black | 10% |
| White | 82% |
| Latino | 13% |
| Diagnosis | |
| Systemic lupus erythematosus (SLE) | 28% |
| Rheumatoid arthritis (RA) | 27% |
| Undifferentiated connective tissue disorder (UCTD) | 8% |
| Psoriatic arthritis | 8% |
| Sjögren syndrome | 4% |
| Mixed connective tissue disorder | 3% |
| Othera | 22% |
| Medications for rheumatic diseaseb | |
| Conventional DMARDs | 84% |
| Biologic DMARDs | 55% |
| Follow-up | |
| Rheumatic disease activity during pandemic | |
| Typical | 36% |
| More active | 31% |
| Less active | 24% |
| Unpredictable | 9% |
| Current status of rheumatic disease | |
| Excellent | 10% |
| Very good | 22% |
| Good | 41% |
| Fair | 21% |
| Poor | 6% |
| How well coped psychologically during pandemic | |
| Very well | 30% |
| Well | 48% |
| Neutral | 15% |
| Fair | 4% |
| Poor | 3% |
a Spondyloarthritis 2%, SLE/UCTD overlap 2%, Sjögren/RA overlap 2%, polymyalgia rheumatica 2%, antiphospholipid syndrome/SLE 2%, ankylosing spondylitis 2%, granulomatosis with polyangiitis 1%, RA/SLE overlap 1%, RA/polymyalgia rheumatica overlap 1%, inflammatory polyarthralgia 1%, small vessel vasculitis 1%, scleroderma 1%, Churg-Strauss syndrome 1%, Still's disease 1%, atypical polyarteritis nodosa 1%, and eosinophilic granulomatosis with polyangiitis 1%.
b Forty-one percent taking both conventional and biologic DMARDs.
FIGURE 1The PROMIS-29 scores at enrollment and follow-up according to whether volunteer COVID-related stress at enrollment; p values are for differences in mean within-patient change. Error bars are for 95% confidence intervals.
Categories of Stress and Coping From Qualitative Analysis
| Sources of Stress | Methods of Coping |
|---|---|
| Overall high stress for everything, taken a toll | Note diminishing stress in multiple areas with time |
| Limitations on coming/going | Stay positive/control mindset |
| Increased family responsibilities | Family pulls together |
| Lost routines/had to make new routines | Take COVID-19 precautions |
| Continued fear of contracting infection | Keep busy at home/keep busy at work |
| Isolation | Recreational activities, including with pets |
| Need to still take precautions | Engage in new self-improvement activities |
| Adverse impact on physical and mental health | Maintain social contacts via telephone/social media |
| Workplace challenges to ensure safety | Adopt a new routine |
| Impeded in-person contact with family/friends | Engage in physical fitness/focus on physical health |
| Impeded in-person contact with general public | Stay outdoors more |
| Adverse impact on employment/finances | Moved out of NYC |
| Witness adverse impact on family/friends | Engage in spiritual activities |
| Moved out of NYC | Start antidepressant/antianxiety medications |
| Uncertainty of current and future course of virus | Obtain professional psychiatric care |
| Inconsistent scientific information about virus | Engage in unhealthy habits and behaviors |
FIGURE 2Coping success at follow-up and associated clinical characteristics, stress, and methods of coping. Change in PROMIS-29 anxiety according to the threshold value for a clinically important difference.
Bivariate and Multivariable Analyses Associated With Coping Worse During Pandemic
| Variables | Bivariate | Initial Multivariable | Final Multivariable | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% Confidence Interval | OR | 95% Confidence Interval | OR | 95% Confidence Interval | ||||
| More PROMIS-measured anxiety at follow-up compared with enrollment | 4.4 | 1.2–15.8 | 0.03 | 4.0 | 1.0–16.5 | 0.05 | 4.4 | 1.1–17.3 | 0.03 |
| Rheumatic disease more active or unpredictable during pandemic | 3.0 | 1.3–6.6 | 0.008 | 1.9 | 0.7–4.8 | 0.19 | — | — | — |
| Disease status at follow-up not excellent/very good | 2.6 | 1.2–6.0 | 0.02 | 2.2 | 0.9–5.7 | 0.10 | 2.7 | 1.1–6.5 | 0.03 |
| High overall stress during pandemic | 4.8 | 1.5–15.2 | 0.008 | 4.0 | 1.1–14.6 | 0.04 | 5.7 | 1.6–20.1 | 0.007 |
| Adverse effects on health during pandemic | 3.4 | 1.2–9.5 | 0.02 | 2.1 | 0.6–6.8 | 0.22 | 3.0 | 1.0–9.0 | 0.05 |
| Adverse effects on employment during pandemic | 3.9 | 1.3–11.5 | 0.01 | 5.4 | 1.6–18.2 | 0.007 | 6.1 | 1.9–20.0 | 0.003 |
| Started antidepressant/antianxiety medications during pandemic | 8.4 | 1.9–38.5 | 0.006 | 3.3 | 0.6–18.2 | 0.16 | — | — | — |
| Engaged in unhealthy behaviors during pandemic | 3.9 | 1.1–13.1 | 0.03 | 1.6 | 0.4–6.8 | 0.52 | — | — | — |
a Based on ordinal logistic regression models.